Please click to send Online Abstract
Guidelines for the Submission of Oral Symposia, Oral Sessions and Oral Platform Presentations
Oral Abstract Submission Guidelines:
A. Conference Program and Content
Abstracts submitted for 8th ICP-4th ISCAP should be prepared in English. Presentations can be made either in English or Turkish since simultaneous translations will be provided. Language preference belongs to the presenter.
Visual elements should be prepared in PowerPoint both in English and Turkish should be given to the audiovisual technician at least 3 hours prior to the programmed talk.
Abstracts of researches and case presentations submitted in English will be published in the CD of abstracts that will be given to all participants during the congress.
Abstracts of peer reviewed and approved research studies which are presented oral and poster sessions at the Turkish Association for Psychopharmacology (TAP)'s 8th International Congress will be published in the Supplement of TAP's official journal, Bulletin of Clinical Psychopharmacology, which is indexed by Science Citation Index Expanded (SCI-E). The abstracts should have four parts of objective, methods, results, and conclusion and should be consisted of minimum 450 and maximum 500 words. For detailed information please visit:
http://www.psikofarmakoloji.org/v2/Default_eng.asp
Session Types in the Program
1.Plenary/Keynote Lectures
The speakers for these sessions are selected by the chairpersons and invited by the Organizing Committee. Further submissions for Plenary/Keynote Lectures are not usually accepted, but if you have an exceptional proposal (as well as prior permission from the proposed speaker where applicable) please contact the 8th ICP-4th ISCAP Congress Secretariat at
psychopharmacology2016.org@burkon.com
• The abstract should be described clearly in no more than 500 words.
2. Oral Symposia
Oral symposia are submitted to the Programming Committee by small groups of individuals who put together a 90-minute symposium with at least 4 speakers and two discussant moderators. The submitting speaker/session organizer must have prior permission from all the proposed speakers and will be the main point of contact responsible for forwarding on any acceptances and other communications, etc., to them.
• The abstract should be described clearly in no more than 500 words
• It should be an accurate reflection of the content of the presentation
• These will be carried out as three parallel sessions.
3. Oral Sessions/ Interactive
These are individual talks of 30 minutes total duration. The speakers are requested to limit their talk to 20-25 minutes to allow some time for discussion and questions.
• The abstract should be described clearly in no more than 500 words.
• It should be an accurate reflection of the content of the presentation.
• These will be carried out as three parallel sessions.
4. Oral Presentations
These are 10 minutes rapid communications, which will be grouped together into six talks at a time, making one-hour sessions. The speakers are required to use no more than 8 slides and speak for 8 minutes, allowing 2 minutes for one question at the end of each talk.
• The abstract should be described clearly in no more than 500 words
• It should be an accurate reflection of the content of the presentation
• These will be carried out as three parallel sessions.
ABSTRACT SUBMISSION GUIDELINES
Abstracts should be prepared according to the following instructions:
Main Topics
Your abstract should be submitted under one of the main topics.
Please click to see the main topics list.
Content
The abstracts of researches should have four parts of objective, methods, results, and conclusion and should be consisted of minimum 450 and maximum 500 words. For detailed information please visit:
http://www.psikofarmakoloji.org/v2/Default_eng.asp
- Objective: indicate the purpose and objective of the research, the hypothesis that was tested or a description of the problem being analyzed or evaluated.
- Methods: describe the study period / setting / location, study design, study
population, data collection and methods of analysis used.
- Results: describe as clearly and in as much detail as possible the findings, outcome of the study. Please summarize any specific results.
- Conclusions: explain the significance of your findings, outcomes of the study, and future implications of the results.
Objectives, methods, results and conclusions are not necessary to be used in case presentation abstracts.
NOTE: Case presentations can only be submitted as a poster.
• Abstracts must report on high quality original research in the field of psychopharmacology, neuroscience, adult psychiatry, and child and adolescent psychiatry that were not been previously published as a whole or in part elsewhere.
• The statements, in particular in the conclusion section, should be balanced.
• Abbreviations or market names (instead of the generic medication names) should not be used.
• Standard abbreviations for well-established psychopharmaceuticals can be used. Place unusual abbreviations in parentheses after the full word the first time it appears. Clearly identify all psychopharmaceuticals mentioned.
• Please indicate a scientific track category of your presentation and a field of research. You are requested to tick one box only.
• A disclosure statement regarding the abstract is requested.
Layout
• All abstracts must be submitted in English.
• Abstracts should have a minimum of 450 and a maximum of 500 words.
• It is the author’s sole responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact in the abstract text will be reproduced as typed by the author.
Authors
• Indicate the author's name(s) and address of the institution on the on-line form.
• State the presenting author as underlined.
Keywords
• Please select three keywords from the list of keywords according to MeSH (Medical Subject Headings), which is the NLM controlled vocabulary thesaurus used for indexing articles for the PubMed.
REST OF THE ABSTRACT GUIDELINE BELOW IS VALID FOR THE RESEARCH STUDIES APPLIED FOR AN AWARD.
References
• No more than three references to previous publications may be included. In the body text, a publication should be referred to by a consecutive number between brackets, i.e., [1], [2] and [3].
The references should be provided in accordance with the following example:
Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-602.
References are not needed in case presentations.
Review process
An abstract is eligible for review when:
• The abstract is submitted according to the guidelines and before the deadline, which is February 01, 2016.
The following review criteria will be used in scoring abstracts submitted:
- Is there a clear background and justified objective?
- Is the methodology/study design appropriate for the objectives?
- Are the results important and clearly presented?
- Are the conclusions supported by the results?
- Is the study original, and does it contribute to the field?
The abstracts submitted will be reviewed for:
• Presentation at the congress as a poster presentation
Poster presentations should be prepared with the size of 70 cm (width) x 90 cm (height).
Oral presentations should be prepared 10 min in total; 8 min for speech and 2 min for discussion.
• Publication in the congress supplement to the journal, Bulletin of Clinical Psychopharmacology
Publication
Abstracts selected for publication will be published congress supplement to the TAP’s official journal, Bulletin of Clinical Psychopharmacology. The publisher of the Bulletin of Clinical Psychopharmacology holds all publication copyrights. Material presented in abstracts should not violate any copyright laws.
Please click to send Online Abstract
|
